Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections (Q43851688)

27 November 2017

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

1 reference

4

Richard E Chaisson

1 reference

27 November 2017

3

Shruti H Mehta

1 reference

27 November 2017

1

Mark S Sulkowski

1 reference

27 November 2017

2

David L Thomas

1 reference

27 November 2017

Richard D Moore

5

1 reference

PubMed ID

11786975

27 November 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

27 November 2017

1 reference

27 November 2017

35

1 reference

27 November 2017

1

1 reference

27 November 2017

182-189

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

27 November 2017

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Slow wave sleep and release of growth hormone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Severe hepatic failure related to nevirapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Jaundice and hepatocellular damage associated with nevirapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Efavirenz-induced acute eosinophilic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Racial differences in the use of drug therapy for HIV disease in an urban community

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Sex differences in nevirapine rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

The tolerability of efavirenz after nevirapine-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

Liver failure after long-term nucleoside antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJHEP.2002.30319

21 January 2018

Identifiers

DOI

10.1053/JHEP.2002.30319

1 reference

27 November 2017

1 reference

PubMed ID

11786975